Christine Bloomquist joins Hogan Lovells in US
This article was originally published in SRA
Executive Summary
Law firm Hogan Lovells has announced that Christine E Bloomquist has joined its health practice in Washington, DC as a partner. Ms Bloomquist will focus her practice on advising pharmaceutical and medical device companies on fraud and abuse compliance and pricing issues as well as on other regulatory and policy matters, including aspects of the Affordable Care Act.
You may also be interested in...
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.
EU Accelerated Assessment Tracker
The EU filing for AstraZeneca’s nirsevimab is being reviewed under the accelerated pathway at the European Medicines Agency. Also, Janssen should know by now whether its planned filing for Zejula plus Zytiga will get the same treatment – as should SIFI for its planned Akantior filing.
AZ Secures EU Fast-Tack Review For Nirsevimab
There could be a regulatory decision on AstraZeneca and Sanofi's nirsevimab in the EU in H2 as a result of the European Medicines Agency speeding up its review of the marketing application for the potential new immunization against RSV in all infants.